Lineage Cell Therapeutics LCTX
NYSE LCTX
$1.08 -0.02 (-1.82%)
As of: Sep 4, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Net Margin (QoQ) (2010 - 2026)

Analysis

Lineage Cell Therapeutics (LCTX) Net Margin (QoQ) (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Lineage Cell Therapeutics 270.71 Mn 213.99 Mn 1.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -52,039.00
Mar 31, 2026 -18,581.00
Dec 31, 2025 -24.00
Sep 30, 2025 60,604.00
Jun 30, 2025 -29,769.00
Mar 31, 2025 -28,795.00
Dec 31, 2024 -3,391.00
Sep 30, 2024 33,060.00
Jun 30, 2024 4,414.00
Mar 31, 2024 -22,839.00
Dec 31, 2023 34,871.00
Sep 30, 2023 -41,314.00
Jun 30, 2023 2,324.00
Mar 31, 2023 14,764.00
Dec 31, 2022 -12,822.00
Sep 30, 2022 -5,505.00
Jun 30, 2022 -1,352.00
Mar 31, 2022 -7,942.00
Dec 31, 2021 28,909.00
Sep 30, 2021 62,462.00